Lantheus Q2 revenue up 22.5% to $394.1M, adjusted EPS $1.80; lowers FY 2024 adjusted EPS guidance to $6.60-$6.70

Lantheus Holdings, Inc.

2024-Q2 EPS reported $2.74 revenue$764,066,000

Revenue $394.1M (+22.5% YoY), driven by PYLARIFY sales $273.3M (+29.8%) and DEFINITY $78.1M (+10.7%).
GAAP diluted EPS $0.88 (vs $1.33); adjusted diluted EPS $1.80 (vs $1.54), +16.4%.
Acquired NAV-4694 (Alzheimer's), global rights to RM2 theranostic pair (prostate/breast), and two preclinical assets from Radiopharm Theranostics.
FY 2024 revenue guidance reaffirmed $1.50-1.52B; adjusted EPS guidance lowered to $6.60-6.70 from $7.00-7.20 due to BD investments.
CMS proposed OPPS rule improves separate payment for diagnostic radiopharmaceuticals like PYLARIFY in hospital outpatient setting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.